Production of lymphotoxin, a bone-resorbing cytokine, by cultured human myeloma cells - PubMed (original) (raw)
Case Reports
Production of lymphotoxin, a bone-resorbing cytokine, by cultured human myeloma cells
I R Garrett et al. N Engl J Med. 1987.
Abstract
Myeloma cells destroy bone by producing an osteoclast-stimulating factor that has chemical and biological characteristics similar to the bone-resorbing activity present in the supernatants of activated leukocyte cultures. Recently, a number of bone-resorbing leukocyte cytokines have been identified, including interleukin-1, lymphotoxin, and tumor necrosis factor. We have examined the products of human myeloma cells for the presence of these bone-resorbing cytokines. In a tumor cell line derived from a patient who had myeloma with osteolytic bone lesions and hypercalcemia, we found that the myeloma cells induced bone-resorbing activity and cytotoxic activity in vitro. Most of the bone-resorbing activity and all cytotoxic activity were suppressed by neutralizing antibodies to lymphotoxin. The myeloma cells expressed both lymphotoxin and tumor necrosis factor mRNA, but no tumor necrosis factor could be detected in the cell-culture medium. Interleukin-1 mRNA was not detected in the myeloma cells, and biologic activity of interleukin-1 was not measurable in the medium harvested from the cultured cells. The bone-resorbing activity induced by recombinant tumor necrosis factor and recombinant interleukin-1 was not affected by treatment with the lymphotoxin antibodies. When lymphotoxin was infused subcutaneously into normal mice (10 micrograms per day for three days), their plasma calcium levels increased. We also evaluated four established cell lines derived from three other patients with myeloma, and found a similar pattern of lymphotoxin expression in each. It appears that production of the bone-resorbing cytokine lymphotoxin is related to osteoclastic bone destruction and hypercalcemia in patients with myeloma.
Similar articles
- Production of interleukin 1 beta, a potent bone resorbing cytokine, by cultured human myeloma cells.
Yamamoto I, Kawano M, Sone T, Iwato K, Tanaka H, Ishikawa H, Kitamura N, Lee K, Shigeno C, Konishi J, et al. Yamamoto I, et al. Cancer Res. 1989 Aug 1;49(15):4242-6. Cancer Res. 1989. PMID: 2787204 - Modulation of osteoclast-activating factor activity of multiple myeloma bone marrow cells by different interleukin-1 inhibitors.
Torcia M, Lucibello M, Vannier E, Fabiani S, Miliani A, Guidi G, Spada O, Dower SK, Sims JE, Shaw AR, Dinarello CA, Garaci E, Cozzolino F. Torcia M, et al. Exp Hematol. 1996 Jul;24(8):868-74. Exp Hematol. 1996. PMID: 8690044 - Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors.
Bertolini DR, Nedwin GE, Bringman TS, Smith DD, Mundy GR. Bertolini DR, et al. Nature. 1986 Feb 6-12;319(6053):516-8. doi: 10.1038/319516a0. Nature. 1986. PMID: 3511389 - Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma.
Klein B, Zhang XG, Jourdan M, Boiron JM, Portier M, Lu ZY, Wijdenes J, Brochier J, Bataille R. Klein B, et al. Eur Cytokine Netw. 1990 Oct-Nov;1(4):193-201. Eur Cytokine Netw. 1990. PMID: 2104241 Review. - Update on the pathogenesis of osteolysis in multiple myeloma patients.
Giuliani N, Colla S, Rizzoli V. Giuliani N, et al. Acta Biomed. 2004 Dec;75(3):143-52. Acta Biomed. 2004. PMID: 15796087 Review.
Cited by
- Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: correlation with disease activity and other prognostic parameters.
Nachbaur DM, Herold M, Maneschg A, Huber H. Nachbaur DM, et al. Ann Hematol. 1991 Feb-Mar;62(2-3):54-8. doi: 10.1007/BF01714900. Ann Hematol. 1991. PMID: 2031968 - Cytokines involved in the progression of multiple myeloma.
Merico F, Bergui L, Gregoretti MG, Ghia P, Aimo G, Lindley IJ, Caligaris-Cappio F. Merico F, et al. Clin Exp Immunol. 1993 Apr;92(1):27-31. doi: 10.1111/j.1365-2249.1993.tb05943.x. Clin Exp Immunol. 1993. PMID: 8467562 Free PMC article. - Role of cytokines in the regulation of bone resorption.
Roodman GD. Roodman GD. Calcif Tissue Int. 1993;53 Suppl 1:S94-8. doi: 10.1007/BF01673412. Calcif Tissue Int. 1993. PMID: 8275387 Review. - Osteoclast cytomorphometry demonstrates an abnormal population in B cell malignancies but not in multiple myeloma.
Chappard D, Rossi JF, Bataille R, Alexandre C. Chappard D, et al. Calcif Tissue Int. 1991 Jan;48(1):13-7. doi: 10.1007/BF02555791. Calcif Tissue Int. 1991. PMID: 1706639
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical